Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Change in Receivables: 2010-2025

Historic Change in Receivables for Cumberland Pharmaceuticals (CPIX) over the last 15 years, with Sep 2025 value amounting to $113,691.

  • Cumberland Pharmaceuticals' Change in Receivables rose 136.78% to $113,691 in Q3 2025 from the same period last year, while for Sep 2025 it was -$880,023, marking a year-over-year increase of 8.53%. This contributed to the annual value of $1.9 million for FY2024, which is 157.07% up from last year.
  • According to the latest figures from Q3 2025, Cumberland Pharmaceuticals' Change in Receivables is $113,691, which was up 166.48% from -$171,014 recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Change in Receivables peaked at $7.8 million during Q1 2022, and registered a low of -$3.4 million during Q2 2021.
  • For the 3-year period, Cumberland Pharmaceuticals' Change in Receivables averaged around -$248,411, with its median value being -$171,014 (2025).
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 4,421.45% in 2022, then crashed by 666.56% in 2024.
  • Over the past 5 years, Cumberland Pharmaceuticals' Change in Receivables (Quarterly) stood at -$3.0 million in 2021, then surged by 30.41% to -$2.1 million in 2022, then declined by 21.54% to -$2.5 million in 2023, then soared by 115.54% to $390,841 in 2024, then spiked by 136.78% to $113,691 in 2025.
  • Its Change in Receivables was $113,691 in Q3 2025, compared to -$171,014 in Q2 2025 and -$1.2 million in Q1 2025.